Bispecific T Cell Engagers | Noopur Raje, MD | ASH 2022

Revlimid Refractory Patients in Daratumumab Clinical Trials | Binod Dhakal, MD | ASH 2022
iStopMM Trial - Covid Vaccine and Impact on Myeloma | Malin Hultcrantz, MD, PhD | ASH 2022
Updates on Teclistamab, Talquetamab, and CARVYKTI | Mark Wildgust, PhD | ASH 2022
Prospective Evaluation of the Biology of Aggressive Myeloma Lesions After Induction | ASH 2022
Detecting Myeloma with Single Cell Sequencing | Scott Goldsmith, MD | ASH 2022
What to Look Forward to at ASH | Ola Landgren, MD, PhD | ASH 2022
(Guest Lecture): Relapsed Refractory Multiple Myeloma - Krina Patel, MD, MSc | RT Irvine, CA Nov 5, 2022
(Guest Lecture) November 2022 - Integrative Medicine: Ideas for Myeloma Treatment
(Guest Lecture): November 2022 - How Myeloma Frontline Therapy is Changing - Ajai Chari, MD
(Guest Lecture): November 2022 - CAR-T: Ready for Prime Time?
(Guest Lecture) November 2022 - Physiatry: A New Approach Incorporating Proven Ideas
Amrita Krishnan Leads Faculty Discussion | RT Irvine, CA Nov 5, 2022
Pushing Toward Tomorrow - Amrita Krishnan, MD, FACP | RT Irvine, CA Nov 5, 2022
Integrative Medicine: Ideas for Myeloma Treatment - Richard Lee, MD | RT Irvine, CA Nov 5, 2022
Relapsed Refractory Multiple Myeloma - Krina Patel, MD, MSc | RT Irvine, CA Nov 5, 2022
CAR-T: Ready for Prime Time? - Jesus Berdeja, MD | RT Irvine, CA Nov 5, 2022